Greg Finak

Biography
Greg Finak leads Ozette Technologies, which builds the analytical and data infrastructure that makes cytometry data decision-grade for clinical development and AI-ready for agentic science. Ozette enables drug developers to draw on their flow cytometry data, including years of historical studies, as structured, annotated, reproducible, traceable datasets in minutes. That data supports patient selection, pharmacodynamic endpoints, response prediction, and regulatory filings. Ozette serves as a secure, permissioned data source for an organization’s own AI agents. Before co-founding Ozette as a Fred Hutch spinout, he spent a decade there building statistical methods for immune monitoring in clinical trials with the HIV Vaccine Trials Network, the Immune Tolerance Network, and Gates Foundation programs in TB and malaria. He led the Human ImmunoPhenotyping Consortium’s multi-center flow cytometry standardization study, built widely used open-source tools for multiomic analysis in vaccine trials, and has published in Nature Medicine, Nature Biotechnology, Science, and The Lancet.